Shire reported another power-packed quarter, with product sales growth of 16% yoy (all sales growth numbers at CER, unless specified otherwise) to $1.6bn. Robust performance of Vyvanse (+23%), Lialda/Mezavant (+14%), Replagal (+12%), HAE portfolio (Firazyr: 40%; Cinryze: +11%) as well as drugs acquired from the NPS acquisition (Gattex/Revestive: sales of $52m; Natpara: sales of $16m), were slightly offset by Intuniv (-39%) and Pentasa (-19%). Higher royalties (+26%), on account of Sensipar (p
04 May 2016
Another strong quarter
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another strong quarter
Shires Income PLC GBP (SHRS:LON) | 222 -1.1 (-0.2%) | Mkt Cap: 92.0m
- Published:
04 May 2016 -
Author:
Kamla Singh -
Pages:
3
Shire reported another power-packed quarter, with product sales growth of 16% yoy (all sales growth numbers at CER, unless specified otherwise) to $1.6bn. Robust performance of Vyvanse (+23%), Lialda/Mezavant (+14%), Replagal (+12%), HAE portfolio (Firazyr: 40%; Cinryze: +11%) as well as drugs acquired from the NPS acquisition (Gattex/Revestive: sales of $52m; Natpara: sales of $16m), were slightly offset by Intuniv (-39%) and Pentasa (-19%). Higher royalties (+26%), on account of Sensipar (p